Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about OrbiMed Leads $9.7M Series A In Cancer Upstart CBT Pharmaceuticals
Venture Capital

OrbiMed Leads $9.7M Series A In Cancer Upstart CBT Pharmaceuticals

by fiercebiotech.com posted 2years ago 2628 views
The Asian unit of perpetual life science backer OrbiMed has led a modest $9.7 million first round for biotech CBT Pharmaceuticals as it looks to build up its c-Met and I/O pipeline of cancer meds.